US Patent

US11529357 — Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine

Formulation · Assigned to H Lundbeck AS · Expires 2040-01-31 · 14y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an injectable pharmaceutical composition of carbamazepine that is essentially free of 10-bromo-carbamazepine.

USPTO Abstract

An injectable pharmaceutical composition comprising carbamazepine and sulfobutylether-7-Î²-cyclodextrin, wherein said composition is essentially free of 10-Br-carbamazepine, is disclosed. Methods for the manufacture of said composition and methods for treatment of disease using said composition are also disclosed.

Drugs covered by this patent

Tegretol (carbamazepine) · Novartis AG (originally Geigy)

Patent Metadata

Patent number: US11529357
Jurisdiction: US
Classification: Formulation
Expires: 2040-01-31
Drug substance claim: No
Drug product claim: Yes
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.